Biogen Inc banner

Biogen Inc
SWB:IDP

Watchlist Manager
Biogen Inc Logo
Biogen Inc
SWB:IDP
Watchlist
Price: 159.96 EUR 2.16% Market Closed
Market Cap: €23.3B

Wall St Price Targets

IDP Price Targets Summary
Biogen Inc

Wall Street analysts forecast IDP stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IDP is 193.84 EUR with a low forecast of 131.16 EUR and a high forecast of 272.72 EUR.

Lowest Forecast
Price Target
131.16 EUR
18% Downside
Average Forecast
Price Target
193.84 EUR
21% Upside
Highest Forecast
Price Target
272.72 EUR
70% Upside
Biogen Inc Competitors:
Price Targets
SSRM
SSR Mining Inc
43% Upside
INO
Inovio Pharmaceuticals Inc
187% Upside
PRQR
ProQR Therapeutics NV
407% Upside
NCSM
NCS Multistage Holdings Inc
58% Upside
CENT
Central Garden & Pet Co
13% Upside

Revenue
Forecast

5% / Year
Past Growth
2% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
5% / Year
Past Growth
2% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 5%. The projected CAGR for the next 8 years is 2%.

Gross Profit
Forecast

3% / Year
Past Growth
3% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
3% / Year
Past Growth
3% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 3%. The projected CAGR for the next 8 years is 3%.

Operating Income
Forecast

2% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
-8%
Average Miss
2% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
-8%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 2%. The projected CAGR for the next 8 years is 6%.

Pre-Tax Income
Forecast

-1% / Year
Past Growth
27% / Year
Estimated Growth
Estimates Accuracy
-15%
Average Miss
-1% / Year
Past Growth
27% / Year
Estimated Growth
Estimates Accuracy
-15%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been -1%. The projected CAGR for the next 3 years is 27%.

Net Income
Forecast

-1% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-18%
Average Miss
-1% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-18%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been -1%. The projected CAGR for the next 8 years is 14%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is IDP's stock price target?
Price Target
193.84 EUR

According to Wall Street analysts, the average 1-year price target for IDP is 193.84 EUR with a low forecast of 131.16 EUR and a high forecast of 272.72 EUR.

What is the Revenue forecast for Biogen Inc?
Projected CAGR
2%

Over the last 13 years, the compound annual growth rate for Revenue has been 5%. The projected CAGR for the next 8 years is 2%.

What is the Gross Profit forecast for Biogen Inc?
Projected CAGR
3%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 3%. The projected CAGR for the next 8 years is 3%.

What is the Operating Income forecast for Biogen Inc?
Projected CAGR
6%

Over the last 13 years, the compound annual growth rate for Operating Income has been 2%. The projected CAGR for the next 8 years is 6%.

What is the Pre-Tax Income forecast for Biogen Inc?
Projected CAGR
27%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been -1%. The projected CAGR for the next 3 years is 27%.

What is the Net Income forecast for Biogen Inc?
Projected CAGR
14%

Over the last 13 years, the compound annual growth rate for Net Income has been -1%. The projected CAGR for the next 8 years is 14%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett